GlassScriptPhysician profile
Racha Halawi
NPI 1841587235
$3,225.36
in general payments reported to CMS, 2019-2025
40 companies · $71.70 in 2025
The $71.70 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.95 · 2021: $131 · 2022: $285 · 2023: $1,747 · 2024: $916 · 2025: $71.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $289.74 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $269.51 | 2023-2025 | |
| Incyte Corporation | $215.27 | 2021-2023 | Monjuvi, Jakafi |
| Rigel Pharmaceuticals, INC. | $187.68 | 2022-2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $164.09 | 2022-2025 | |
| Abbvie INC. | $144.84 | 2023-2025 | |
| Daiichi Sankyo INC. | $143.16 | 2023-2024 | Vanflyta |
| Glaxosmithkline, LLC. | $103.16 | 2022-2024 | Ojjaara, Shingrix |
| Pharmaessentia USA Corporation | $96.01 | 2023-2024 | Besremi |
| Karyopharm Therapeutics INC. | $95.76 | 2023-2024 | Xpovio |
| Seagen INC. | $95.35 | 2022-2023 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $91.36 | 2022-2024 | Iclusig, Ninlaro |
| Emmaus Medical, INC. | $88.29 | 2023-2024 | Endari |
| Astellas Pharma US INC | $85.80 | 2023-2024 | Xospata |
| Adaptive Biotechnologies Corporation | $81.83 | 2023 | Clonoseq |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Racha Halawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.